SOLICITATION NOTICE
Q -- quantitative polymerase chain reaction follow-up of SABRe CVD Gene Expression analysis discovery work
- Notice Date
- 9/12/2011
- Notice Type
- Presolicitation
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- NHLBI-CSB-(HL)-2011-355-DDC
- Archive Date
- 10/1/2011
- Point of Contact
- Deborah - Coulter, Phone: (301) 435-0368
- E-Mail Address
-
dc143b@nih.gov
(dc143b@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- THIS IS A NOTICE OF INTENT, NOT A REQUEST FOR A PROPOSAL. A SOLICITATION DOCUMENT WILL NOT BE ISSUED AND PROPOSALS WILL NOT BE REQUESTED. The COAC Services Branch, Office of Acquisitions, DERA, National Heart, Lung, and Blood Institute (NHLBI), NIH, for the Framingham Heart Study under the NHLBI, Division of Intramural Research (DIR) Center for Population Studies, intends to award a purchase order on a sole source basis for the purchase of qPCR follow-up of SABRe CVD Gene Expression analysis discovery work; services from the University of Massachusetts. The reference number: NHLBI-CSB-(HL)-2011-355-DDC. Background: Framingham SABRe CVD Initiative will assess biomarkers in approximately 7000 Framingham Heart Study Offspring and Third Generation cohort participants. Thousands of biomarkers will be assessed using the following platforms: a) immunoassays, b) discovery and targeted proteomics, c) discovery and targeted metabolomics/lipomics, and WBC derived RNA expression. SABRe CVD represents an opportunity to conduct complex systems biology science on a population level. In this collaborative effort in biomarker discovery, the NHLBI genomics core has undertaken the biomarker discovery project for analysis of ~7000 samples on Human Exon arrays to identify differentially expressed genes and associated alternative splicing events using the Affymetrix Platform. Specifically, the Government will identify genes with altered expression in heart, lung, and blood disorders, and in parallel study alternative splicing events during the disease process. This study will be conducted in phases and we intend to start analyzing gene expression in Paxgene blood samples which have already been collected from Framingham Heart Study Offspring participants. This project involves the contractor performing the genotyping of genes from SABRe CVD Gene Expression Study. Purpose: This purpose of this project is to validate results obtained from the SABRe CVD project-3 Gene Expression analysis study of Framingham Heart Study samples from Buffy Coat. There are many interesting genes demonstrating mean fold changes of an interesting level across several different disease models. This qPCR study will attempt to replicate and validate the initial results obtained from the array technology used in the expression analysis study by an orthogonal means of measuring the levels of these selected genes. Period of Performance: Upon receipt of purchase order ending on December 30th 2012. Contractor Requirements: A. Contractor shall provide genotyping services. The contractor will process existing SABRe CVD Study samples at contractor location using standard genotyping methods. a. Phase I shall include 96 genes and 440 samples b. Phase II shall follow Phase I and contain 20 genes and >1000 samples B. The Contractor shall provide high quality assay results with: a. Blind duplicates with concordant results >95% C. Quality control measures shall be applied by the Contractor and assay results will be accompanied by quality control information reflecting SNP QC. D. Contractor shall specify any special packaging, marking, or shipping instructions for sample shipment. Government Responsibilities: A. NHLBI shall provide the list of genes to be studied 6-weeks in advance to allow proper reagent and primer design B. NHLBI will provide the complete list of subjects to be studied and the necessary 200ng of RNA for the qPCR reactions. Reporting Requirements and Deliverables: C. Genotype results will be returned by Contractor to the Framingham Heart Study in a standard format in a nonproprietary database in which each gene is identified by a standard name. D. Return of gene results by the Contractor will be accompanied by summary quality control measures for each gene. E. Gene results will be returned to the Study within a mutually agreed upon timeline tied to the receipt of the gene list and appropriate RNA samples identified. Program Management and Control Requirements: No special management or control systems are required under this contract. The sole source determination is based on the fact that University of Massachusetts, High Throughput Gene Expression Biomarker Core Laboratory is a major collaborator of the SABRe CVD initiative. This laboratory is conduction the miRNA analysis in conjunction with the SABRe CVD. This analysis of gene expression hits for validation utilized the same samples this laboratory is using to conduct the miRNA analysis; therefore this is the only lab that can conduct this analysis. The current samples are precious non-renewable resources and keeping them in tack in the original laboratory is obviously the best approach for the science, sample integrity and work flow to complete these analyses. The delivery point is the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), Framingham Heart Study, 73 Mt. Watye Avenue Perini Building, Framingham MA 01702. The notice of intent is not a request for competitive proposals. Only one responsible source and no other supplies or services will satisfy agency requirements. Industry Classification (NAICS) Code is 541380, Testing Laboratories with size standard of $12.0M; the small business set-aside does not apply for this requirement. The acquisition is being conducted under FAR Part 13, simplified acquisition procedures, therefore the requirements of FAR Part 6 B Competitive Requirements are not applicable (FAR Part 6.001) and the resultant purchase order will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 05-53 (August 4th 2011). This notice of intent is not a request for competitive proposals. Interested parties may identify their interest and capabilities in response to this synopsis, by September 16th 2011, 7:30 am Eastern Standard Time. The determination by the Government not to compete the proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct future competitive procurement. Inquires to this announcement, referencing synopsis number NHLBI-CSB-(HL)-2011-355-DDC, may be submitted to the COAC Services Branch, Office of Acquisitions, DERA, National Heart, Lung, and Blood Institute (NHLBI), NIH, 6701 Rockledge Drive, Suite 6042, Bethesda, Maryland 20892-7902, Attention: Deborah Coulter. Response may be submitted electronically to coulterd@nhlbi.nih.gov. Faxes will not be accepted. Responses will only be accepted if dated and signed by an authorized company representative.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/NHLBI-CSB-(HL)-2011-355-DDC/listing.html)
- Place of Performance
- Address: Framingham Heart Study, Framingham, Massachusetts, 01702, United States
- Zip Code: 01702
- Zip Code: 01702
- Record
- SN02572057-W 20110914/110912235631-ef7ce171c34b8ba02a8d179c5731161a (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |